2025/07/02 更新

所属以外の情報はresearchmapへの登録情報を転載しています。

写真a

マスイ ケンイチ
増井 健一
Kenichi Masui
所属
医学研究科 医科学専攻 麻酔科学 准教授
医学部 医学科
職名
准教授
外部リンク

学位

  • 博士(医学) ( 山梨大学 )

研究キーワード

  • 薬力学

  • 麻酔薬理学

  • 薬物動態学

  • ファーマコメトリクス

  • コンピュータシミュレーション

  • 筋弛緩薬

  • 膠原病

  • 麻薬

  • 静脈麻酔薬

研究分野

  • ライフサイエンス / 麻酔科学

  • ライフサイエンス / 医療薬学

学歴

  • 山梨医科大学   医学部   医学科

    1991年 - 1997年

      詳細を見る

    国名: 日本国

    researchmap

経歴

  • 横浜市立大学   医学部 麻酔科学   准教授

    2022年 - 現在

      詳細を見る

  • 横浜市立大学   医学部 麻酔科学   特任准教授

    2021年 - 2022年

      詳細を見る

  • 昭和大学   麻酔科学講座   講師

    2017年 - 2021年

      詳細を見る

  • 防衛医科大学校   麻酔学講座   講師

    2010年 - 2017年

      詳細を見る

  • 防衛医科大学校   麻酔学講座   助教

    2007年 - 2010年

      詳細を見る

  • ゲント大学(ベルギー)   麻酔科学講座   研究員

    2007年 - 2008年

      詳細を見る

  • 防衛医科大学校   麻酔学講座   助手

    2005年 - 2007年

      詳細を見る

  • 諏訪中央病院   麻酔科   医長

    2004年 - 2005年

      詳細を見る

  • 山梨医科大学   麻酔科学教室   助手

    2002年 - 2004年

      詳細を見る

  • 諏訪中央病院   麻酔科   医師

    2000年 - 2002年

      詳細を見る

  • 山梨医科大学   麻酔科学教室   助手

    1997年 - 2000年

      詳細を見る

▼全件表示

所属学協会

  • 日本小児麻酔学会

    2022年9月 - 現在

      詳細を見る

  • 日本臨床麻酔学会

      詳細を見る

  • 日本静脈麻酔学会

      詳細を見る

  • 日本麻酔集中治療テクノロジー学会

      詳細を見る

  • 日本麻酔科学会

      詳細を見る

  • American Socciety of Anesthesiologists

      詳細を見る

▼全件表示

委員歴

  • World Society of Intravenous Anaesthesia   Director  

    2025年4月 - 現在   

      詳細を見る

  • 日本麻酔・集中治療テクノロジー学会   選任理事  

    2024年10月 - 現在   

      詳細を見る

  • 日本麻酔科学会, 事務局委員  

    2024年7月 - 現在   

      詳細を見る

  • 日本小児麻酔学会   臨床研究推進委員会 委員  

    2023年10月 - 現在   

      詳細を見る

  • 日本麻酔科学会   代議員  

    2023年6月 - 現在   

      詳細を見る

  • Scientific Reports, Editorial Board  

    2022年11月 - 2024年3月   

      詳細を見る

  • JA Clinical Report   Section Editor  

    2021年3月 - 現在   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本静脈麻酔学会   理事  

    2019年11月 - 現在   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本麻酔科学会   学術研究審査委員会  

    2017年6月 - 2023年6月   

      詳細を見る

  • 日本麻酔科学会   学術委員会  

    2017年6月 - 2021年6月   

      詳細を見る

    団体区分:学協会

    researchmap

  • Journal of Anesthesia   Section Editor  

    2017年3月 - 現在   

      詳細を見る

    団体区分:学協会

    researchmap

  • British Journal of Anaesthesia   Associate Editorial Board  

    2012年2月 - 2020年9月   

      詳細を見る

  • 日本麻酔集中治療テクノロジー学会   評議員  

    2006年12月 - 現在   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本静脈麻酔学会   評議員  

    2005年12月 - 2019年11月   

      詳細を見る

    団体区分:学協会

    researchmap

▼全件表示

論文

  • Umbilical analgesic concentrations after labour analgesia with programmed intermittent epidural bolus: a prospective observational study. 査読 国際誌

    Arisa Ijuin, Masaki Sato, Nagayoshi Umehara, Shoichiro Amari, Jumpei Saito, Mayuko Abe, Wataru Matsunaga, Yoko Yamashita, Yasuyuki Suzuki, Kenichi Masui

    Canadian journal of anaesthesia = Journal canadien d'anesthesie   2025年6月

     詳細を見る

    担当区分:筆頭著者, 最終著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: The umbilical analgesic concentrations after using programmed intermittent epidural bolus (PIEB) and patient-controlled epidural analgesia (PCEA) without continuous infusion are unknown. We aimed to characterize umbilical ropivacaine and fentanyl concentrations and examine their influence on neonatal conditions at delivery. METHODS: We prospectively studied 50 parturients with singleton pregnancies who received combined spinal-epidural analgesia using PIEB (7 mL every 45 min) and PCEA (7 mL per bolus; lockout interval: 15 min) with 0.08% ropivacaine and 2 μg·mL-1 fentanyl, with clinician-administered boluses as necessary. We evaluated the umbilical venous analgesic concentrations and neonatal characteristics. RESULTS: The median [interquartile range (IQR)] hourly ropivacaine and fentanyl doses were 13 [11-15] mg·hr-1 and 39 [30-50] µg·hr-1, respectively. The ropivacaine and fentanyl concentrations were 77 [56-98] ng·mL-1 and 0.125 [0.125-0.20] ng·mL-1 at delivery, respectively. The umbilical analgesic concentrations were correlated with the labour duration and total dose. In parturients given clinician-administered boluses within 1 hr before delivery, the ropivacaine and fentanyl concentrations were similar to those without (81 [54-104] vs 77 [54-96] ng·mL-1 and 0.20 [0.125-0.20] vs 0.125 [0.05-0.20] ng·mL-1, respectively). The umbilical arterial pH was > 7.2 and the Apgar score at 5 min was ≥ 8 for all neonates. No neonates exhibited systemic local anesthetic toxicity. Respiratory support was required for 14 neonates. CONCLUSIONS: Umbilical analgesic concentrations at delivery were low after labour analgesia using a regimen of PIEB with PCEA for up to 19 hr. An intermittent bolus dosing regimen may contribute to a decrease in umbilical analgesic concentrations.

    DOI: 10.1007/s12630-025-02975-7

    PubMed

    researchmap

  • Remimazolam anesthesia in pediatric patients undergoing cardiac catheterization for congenital heart disease: a retrospective observational study. 査読

    Maiko Hosokawa, Yurie Takahashi, Takahiro Ueno, Katsunori Oe, Kenichi Masui

    Journal of anesthesia   2024年8月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Benzodiazepines are used in pediatric patients with congenital heart disease (CHD) because of their mild hemodynamic depressant effects. A novel short-acting benzodiazepine, remimazolam, is expected to be suitable for these patients. We examined the characteristics of remimazolam anesthesia in pediatric patients with CHD undergoing cardiac catheterization. METHODS: This single-center retrospective study included pediatric patients undergoing cardiac catheterization for CHD. The primary outcome was the remimazolam dose for loss of consciousness. Secondary outcomes included the mean maintenance remimazolam dose, recovery time from anesthesia, predicted remimazolam concentration at emergence, decrease in blood pressure and heart rate, vasopressor administration during anesthesia, electroencephalogram index (bispectral index: BIS or patient state index: PSI), and life-threatening adverse events. RESULTS: Thirty-nine patients, aged 2 months to 16 years, were included. Thirty-three patients received a median [interquartile] midazolam dose of 0.10 [0.10-0.10] mg.kg-1 in the pre-anesthesia room. The remimazolam dose for loss of consciousness was 0.34 [0.26-0.45] mg.kg-1. The mean maintenance dose was 1.0 [0.8-1.4] mg.kg-1.h-1. The recovery time was 15 [12-17] min. The predicted remimazolam concentration at emergence was 0.4-1.2 µg.ml-1 in 3-6-year-old patients. Blood pressure and heart rate decreased by 30% in 15 and 6 patients, respectively. Vasopressors were administered as a bolus in 8 patients. The BIS or PSI did not fall ≤ 60 or ≤ 50, respectively, in 51% of patients before tracheal intubation. No life-threatening adverse events were reported. CONCLUSIONS: Remimazolam is a good alternative anesthetic agent for pediatric patients undergoing cardiac catheterization for CHD.

    DOI: 10.1007/s00540-024-03395-5

    PubMed

    researchmap

  • Remimazolam: its clinical pharmacology and evolving role in anesthesia and sedation practice. 招待 査読 国際誌

    Kenichi Masui

    Current opinion in anaesthesiology   37 ( 4 )   344 - 351   2024年8月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Ovid Technologies (Wolters Kluwer Health)  

    Purpose of review

    Remimazolam is a novel benzodiazepine anesthetic/sedative, designed as a rapidly metabolized carboxylic acid. Since its recent launch, the role of remimazolam in modern anesthesia and sedation practice is still evolving. This review aims to outline the clinical pharmacology and clinical utility of remimazolam to elucidate its potential advantages and limitations.

    Recent findings

    Remimazolam is “short-acting” but not ultra-short-acting compared with propofol based on context-sensitive decrement times. But compared to propofol, the availability of the benzodiazepine antagonist, flumazenil, is considered an advantage, particularly in certain emergency situations such as in patients with difficult airways. However, because flumazenil is shorter acting than remimazolam when remimazolam accumulates or is present in a high concentration, the reappearance of remimazolam sedation may occur after the initial reversal of anesthesia/sedation from flumazenil administration. Although it is beneficial that remimazolam causes less respiratory depression and hypotension than propofol, serious respiratory depression and hypotension can still occur. Remimazolam administration causes minimal or no pain on injection. Remimazolam is associated with less postoperative nausea and vomiting than inhaled anesthetics, but propofol is clearly superior in this regard. The anesthetic/sedative effects may be prolonged by severe hepatic impairment; remimazolam tolerance can occur in long-term benzodiazepine users.

    Summary

    Remimazolam may be beneficial to use in procedural sedation and general anesthesia for patients with difficult airways or hemodynamic instability. Further clinical studies with remimazolam are warranted to identify the potential benefits in other settings and patient populations.

    DOI: 10.1097/ACO.0000000000001384

    PubMed

    researchmap

  • Hypotension after general anaesthesia induction using remimazolam or propofol in geriatric patients undergoing sevoflurane anaesthesia with remifentanil: a single-centre, double-blind, randomised controlled trial. 査読 国際誌

    Ryuki Takaki, Masashi Yokose, Takahiro Mihara, Yusuke Saigusa, Hiroyuki Tanaka, Natsuhiro Yamamoto, Kenichi Masui, Takahisa Goto

    British journal of anaesthesia   133 ( 1 )   24 - 32   2024年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The occurrence of hypotension after induction of general anaesthesia is common in geriatric patients, and should be prevented to minimise perioperative complications. Compared with propofol, remimazolam potentially has a lower incidence of hypotension. This study aimed to compare the incidence of hypotension after general anaesthesia induction with remimazolam or propofol in geriatric patients. METHODS: This single-centre, double-blind, randomised trial enrolled 90 patients aged ≥80 yr who received general anaesthesia for scheduled surgery. Patients were randomised to receive remimazolam (12 mg kg-1 h-1) or propofol (0.025 mg kg-1 s-1) for anaesthesia induction, with remifentanil and sevoflurane. The presence or absence of hypertension on the ward served as the stratification factor. The incidence of hypotension after the induction of general anaesthesia, defined as a noninvasive mean arterial pressure of <65 mm Hg measured every minute from initiation of drug administration to 3 min after tracheal intubation, was the primary outcome. Subgroup analysis was performed for the primary outcome using preoperative ward hypertension, clinical frailty scale, Charlson Comorbidity Index, and age. RESULTS: Three subjects were excluded before drug administration, and 87 subjects were included in the analysis. The incidence of hypotension was 72.1% (31/43) and 72.7% (32/44) with remimazolam or propofol, respectively. No statistically significant differences (adjusted odds ratio, 0.96; 95% confidence interval, 0.37-2.46; P=0.93) were observed between groups. Subgroup analysis revealed no significant differences between groups. CONCLUSIONS: Compared with propofol, remimazolam did not reduce the incidence of hypotension after general anaesthesia induction in patients aged ≥80 yr. CLINICAL TRIAL REGISTRATION: UMIN000042587.

    DOI: 10.1016/j.bja.2024.04.013

    PubMed

    researchmap

  • What are standard monitoring devices for anesthesia in future? 査読

    Shinju Obara, Naoyuki Hirata, Satoshi Hagihira, Keisuke Yoshida, Yoshifumi Kotake, Shunichi Takagi, Kenichi Masui

    Journal of anesthesia   2024年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Monitoring the patient's physiological functions is critical in clinical anesthesia. The latest version of the Japanese Society of Anesthesiologists' Guidelines for Safe Anesthesia Monitoring, revised in 2019, covers various factors, including electroencephalogram monitoring, oxygenation, ventilation, circulation, and muscle relaxation. However, with recent advances in monitoring technologies, the information provided has become more detailed, requiring practitioners to update their knowledge. At a symposium organized by the Journal of Anesthesia in 2023, experts across five fields discussed their respective topics: anesthesiologists need to interpret not only the values displayed on processed electroencephalogram monitors but also raw electroencephalogram data in the foreseeable future. In addition to the traditional concern of preventing hypoxemia, monitoring for potential hyperoxemia and the effects of mechanical ventilation itself will become increasingly important. The importance of using AI analytics to predict hypotension, assess nociception, and evaluate microcirculation may increase. With the recent increase in the availability of neuromuscular monitoring devices in Japan, it is important for anesthesiologists to become thoroughly familiar with the features of each device to ensure its effective use. There is a growing desire to develop and introduce a well-organized, integrated "single screen" monitor.

    DOI: 10.1007/s00540-024-03347-z

    PubMed

    researchmap

  • Anesthesia management for thoracoscopic resection of a huge intrathoracic meningocele: a case report. 査読 国際誌

    Ryosuke Nakazawa, Kenichi Masui, Takahisa Goto

    JA clinical reports   10 ( 1 )   14 - 14   2024年2月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Diagnosed intrathoracic meningocele is an uncommon complication of neurofibromatosis type 1. We report an anesthesia management for a rare case undergoing thoracoscopic resection of a huge intrathoracic meningocele. CASE PRESENTATION: A 51-year-old woman was scheduled for thoracoscopic meningectomy under general anesthesia. We monitored intrathecal pressure during anesthesia to prevent a decrease in intrathecal pressure. During surgery, the intrathecal pressure occasionally increased by around 5 cmH2O immediately after the insertion of the drainage tube and occasionally decreased by up to 10 cmH2O during the careful slow aspiration of the cerebrospinal fluid (CSF). The pressure rapidly recovered after the interruption of the procedures. She was discharged on postoperative day 4 without major complications. CONCLUSIONS: The CSF pressure was fluctuated by procedures during thoracoscopic resection of a huge meningocele. A CSF pressure monitoring was useful to detect the sudden change of CSF pressure immediately, which can cause intracranial hemorrhage.

    DOI: 10.1186/s40981-024-00697-1

    PubMed

    researchmap

  • Monitored Anesthesia Care Under a Combination of Low-Dose Remimazolam Infusion and Flumazenil Antagonism: A Case Report

    Kotoe Kamata, Kenichi Masui

    Cureus   2023年10月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    DOI: 10.7759/cureus.46728

    researchmap

  • Reply to "Re-sedation after a large dose of flumazenil". 査読

    Kenichi Masui

    Journal of anesthesia   37 ( 1 )   162 - 163   2023年2月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    DOI: 10.1007/s00540-022-03123-x

    PubMed

    researchmap

    その他リンク: https://link.springer.com/article/10.1007/s00540-022-03123-x/fulltext.html

  • Equilibration rate constant, ke0, to determine effect-site concentration for the Masui remimazolam population pharmacokinetic model in general anesthesia patients. 査読

    Kenichi Masui, Satoshi Hagihira

    Journal of anesthesia   36 ( 6 )   757 - 762   2022年12月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Effect-site concentration is widely used to determine drug dosage in anesthesia practice. To obtain effect-site concentration, a pharmacokinetic model with a corresponding equilibration rate constant between plasma and effect-site, ke0, is necessary. Remimazolam, a novel short-acting benzodiazepine, has been approved as anesthetic/sedative. Recently, a remimazolam pharmacokinetic model has been published using a large dataset including wide range of subject characteristics (416 males and 246 females, age 18-93 years, total body weight 34-149 kg, height 133-204 cm, body mass index 14-61 kg m-2, ASA physical status: I-IV, and Asian, White, American African, and 2 other races). This Masui model can be applicable to various patients, but a pharmacodynamic model including ke0 was not developed simultaneously. A previous article has indicated that the time to peak effect of drug after its bolus should be used to determine ke0 for a pharmacokinetic model without simultaneous development of corresponding pharmacodynamic model. The ke0 value can be calculated using numerical analysis but not algebraic solution. We provide the detail method of the numerical analysis and a tool to have ke0 value easily for the Masui remimazolam PK model. Additionally, we provide a multiple regression model to have ke0 value for the PK model.

    DOI: 10.1007/s00540-022-03099-8

    PubMed

    researchmap

  • Caution!! Reappearance of remimazolam effect after a flumazenil bolus: a larger bolus of flumazenil and a lower total remimazolam clearance are higher risks. 査読

    Kenichi Masui

    Journal of anesthesia   2022年9月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語  

    DOI: 10.1007/s00540-022-03107-x

    PubMed

    researchmap

  • Hypotension after general anesthesia induction using remimazolam in geriatric patients: Protocol for a double-blind randomized controlled trial. 査読 国際誌

    Masashi Yokose, Ryuki Takaki, Takahiro Mihara, Yusuke Saigusa, Natsuhiro Yamamoto, Kenichi Masui, Takahisa Goto

    PloS one   17 ( 9 )   e0275451   2022年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    INTRODUCTION: In geriatric patients, hypotension is often reported after general anesthesia induction using propofol. Remimazolam is a novel short-acting sedative. However, the incidence of hypotension after general anesthesia induction using remimazolam in geriatric patients remains unclear. This study aims to compare the incidence of hypotension associated with remimazolam and propofol in patients aged ≥80 years. METHODS: This single-center, double-blind, randomized, two-arm parallel group, standard treatment-controlled, interventional clinical trial will include 90 patients aged ≥80 years undergoing elective surgery under general anesthesia who will be randomized to receive remimazolam or propofol for induction. The primary outcome is the incidence of hypotension after general anesthesia induction, occurring between the start of drug administration and 3 min after intubation. We define hypotension as mean blood pressure <65 mmHg. The primary outcome will be analyzed using the full analysis set. The incidence of hypotension in the two groups will be compared using the Mantel-Haenszel χ2 test. Subgroup analysis of the primary outcome will be performed based on the Charlson comorbidity index, clinical frailty scale, hypertension in the ward, and age. Secondary outcomes will be analyzed using the Fisher's exact test, Student's t test, and Mann-Whitney U test, as appropriate. Logistic regression analysis will be performed to explore the factors associated with the incidence of hypotension after anesthesia induction. DISCUSSION: Our trial will determine the efficacy of remimazolam in preventing hypotension and provide evidence on the usefulness of remimazolam for ensuring hemodynamic stability during general anesthesia induction in geriatric patients. TRIAL REGISTRATION: The study has been registered with UMIN Clinical Trials Registry (UMIN000042587), on June 30, 2021.

    DOI: 10.1371/journal.pone.0275451

    PubMed

    researchmap

  • A population pharmacokinetic model of remimazolam for general anesthesia and consideration of remimazolam dose in clinical practice. 査読

    Kenichi Masui, Thomas Stöhr, Marija Pesic, Tomohiro Tonai

    Journal of anesthesia   2022年6月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Remimazolam besylate is a novel short-acting benzodiazepine. An appropriate pharmacokinetic model of remimazolam is desirable in anesthesia practice. The aim of the study was to develop a pharmacokinetic model using plasma samples from patients anesthetized with remimazolam. Influence of patient characteristics, context-sensitive decrement-times, and dose regimens were also examined. METHODS: Data were obtained from four trials on patients, and seven trials on healthy volunteers. The characteristics of 416 male and 246 female subjects were as follows: age, 18-93 years; body weight, 34-149 kg; and American Society of Anesthesiologists physical status (ASA-PS), I-IV. 2231 arterial and 3200 venous samples were used for the final model. The equilibration rate constant between arterial plasma and effect-site was estimated using the concept of time to peak effect. The final model was used to generate context-sensitive decrement times and dose regimens for general anesthesia. RESULTS: A three-compartment model plus virtual venous compartment with allometric scaling of adjusted body weight (ABW), age, sex, and ASA-PS as covariates were selected as the final model. Elimination clearance was lower in males, and in subjects with higher ABW and ASA-PS scores. Approximately 10% or 20% higher dose rate was necessary in females than in males or ASA-PS I/II than III/IV patient. The context-sensitive half-time for effect-site concentration in a 55-year-old, 70-kg, 170-cm male or female ASA-PS I/II patient after > 6-h infusion was 16.7 or 15.9 min. CONCLUSION: Remimazolam pharmacokinetic model for general anesthesia was successfully developed. ABW, ASA-PS, and sex has a considerable impact on the remimazolam concentration.

    DOI: 10.1007/s00540-022-03079-y

    PubMed

    researchmap

  • Mortality Risk Stratification Using Cluster Analysis in Patients With Myositis-Associated Interstitial Lung Disease Receiving Initial Triple-Combination Therapy 査読 国際誌

    Takahisa Gono, Kenichi Masui, Shinji Sato, Masataka Kuwana

    Frontiers in Medicine   9   883699 - 883699   2022年5月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Frontiers Media SA  

    Objective

    To stratify patients with polymyositis/dermatomyositis-associated interstitial lung disease (ILD) who were initially treated with an intensive regimen consisting of high-dose corticosteroids, a calcineurin inhibitor, and intravenous cyclophosphamide (triple-combo therapy) into subgroups based on mortality outcomes by a cluster analysis using a large-scale multicenter retrospective cohort of Japanese patients with myositis-associated ILD (JAMI).

    Methods

    Two-step cluster analysis of preclustering and subsequent hierarchical clustering was conducted in 185 patients who received triple-combo therapy in an unbiased manner. Initial predictors for mortality previously reported in patients with myositis-associated ILD were used as variables and included age, sex, disease duration, classification of myositis, requirement of supplemental oxygen, anti-aminoacyl tRNA synthetase (ARS) antibody, anti-melanoma differentiation-associated gene 5 (MDA5) antibody, and serum levels of C-reactive protein (CRP) and Krebs von den Lungen-6 (KL-6). The cluster model was further applied to 283 patients who received conventional regimens consisting of corticosteroids with or without a single immunosuppressive agent (dual-combo therapy or monotherapy). Cumulative survival rates were compared using Kaplan-Meier analysis, and the log-rank test was used to test for significant differences between two groups.

    Results

    We developed a cluster model consisting of 6 clusters, which were categorized by age at onset, clinically amyopathic dermatomyositis, CRP, KL-6, requirement of supplemental oxygen, anti-ARS antibody, and anti-MDA5 antibody. This model was judged to be of good quality based on the silhouette measure of cohesion and separation of 0.6. These clusters were regrouped into three subsets based on low (&amp;lt;10%), moderate (10-50%), and high (&amp;gt;50%) mortality rates. The performance of the clustering was generally replicated in patients who received initial dual-combo therapy or monotherapy. Survival benefits of triple-combo therapy over dual-combo therapy or monotherapy were not observed in any of the clusters.

    Conclusion

    We successfully developed a cluster model that stratified patients with myositis-associated ILD who were treated with initial triple-combo therapy into subgroups with different prognoses, although this model failed to identify a patient subgroup that showed survival benefits from triple-combo therapy over dual-combo therapy or monotherapy.

    DOI: 10.3389/fmed.2022.883699

    PubMed

    researchmap

  • Lateral position for difficult intubation in a patient with history of hemiglossectomy and flap reconstruction: a case report. 査読 国際誌

    Fumiko Yokogawa, Katsunori Oe, Maiko Hosokawa, Kenichi Masui

    JA clinical reports   8 ( 1 )   16 - 16   2022年3月

     詳細を見る

    担当区分:最終著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Reconstructive head and neck surgery can alter upper airway anatomy. We report a difficult intubation in a patient with a history of hemiglossectomy and reconstruction. CASE PRESENTATION: A 65-year-old female patient, who had undergone hemiglossectomy with the flap reconstruction, underwent video-assisted thoracoscopic esophagectomy for esophageal cancer. After the loss of consciousness during anesthesia induction, we failed to perform direct and oral fiberoptic intubation using a video laryngoscope and nasal fiberoptic intubation without or with video laryngoscope assistance in the supine position. Finally, shifting the patient to the left-lateral position allowed successful nasal fiberoptic intubation. Postoperatively, we were informed that she was unable to sleep in the supine position because of airway obstruction and therefore always slept on her side. CONCLUSION: Preanesthetic evaluation of the influence of body position on the airway patency during sleep or sedation may aid in airway management.

    DOI: 10.1186/s40981-022-00509-4

    PubMed

    researchmap

  • Remimazolam Tolerance in Long-term Benzodiazepine Users: A Case Report of 2 Cases. 査読 国際誌

    Haruka Yoshikawa, Maiko Hosokawa, Yuki Kashima, Sayaka Oki, Kenichi Masui

    A&A practice   15 ( 5 )   e01460   2021年5月

     詳細を見る

    担当区分:最終著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    A 60-year-old woman with a 5-year history of anxiolytic use, a diazepam-equivalent daily dose of 15 mg, was scheduled for esophageal stent removal. She was given remimazolam (0.5 mg/kg) but remained fully alert. She only lost consciousness with propofol (40 mg). A 61-year-old man with a 1-year history of anxiolytic use, diazepam-equivalent daily dose of 20 mg, was scheduled for hand tumor resection. He was given remimazolam (0.3 mg/kg) but remained fully alert. He only lost consciousness after desflurane inhalation. In a patient with a history of long-term benzodiazepine use, anesthetic or sedative agents aside from remimazolam should be considered.

    DOI: 10.1213/XAA.0000000000001460

    PubMed

    researchmap

  • Propofol infusions using a human target controlled infusion (TCI) pump in chimpanzees (Pan troglodytes). 査読 国際誌

    T Miyabe-Nishiwaki, A Kaneko, A Yamanaka, N Maeda, J Suzuki, M Tomonaga, T Matsuzawa, K Muta, R Nishimura, I Yajima, D J Eleveld, A R Absalom, K Masui

    Scientific reports   11 ( 1 )   1214 - 1214   2021年1月

     詳細を見る

    担当区分:最終著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Chimpanzees are genetically and physiologically similar to humans. Several pharmacokinetic models of propofol are available and target controlled infusion (TCI) of propofol is established in humans, but not in chimpanzees. The purpose of this study was to investigate if human pharmacokinetic models can accurately predict propofol plasma concentration (Cp) in chimpanzees and if it is feasible to perform TCI in chimpanzees. Ten chimpanzees were anaesthetized for regular veterinary examinations. Propofol was used as an induction or maintenance agent. Blood samples were collected from a catheter in a cephalic vein at 3-7 time points between 1 and 100 min following the propofol bolus and/or infusion in five chimpanzees, or TCI in six chimpanzees. Cp was measured using high-performance liquid chromatography. The Marsh, Schnider and Eleveld human pharmacokinetic models were used to predict Cp for each case and we examined the predictive performances of these models using the Varvel criteria Median PE and Median APE. Median PE and Median APE for Marsh, Schnider and Eleveld models were within or close to the acceptable range. A human TCI pump was successfully maintained propofol Cp during general anesthesia in six chimpanzees. Human propofol pharmacokinetic models and TCI pumps can be applied in chimpanzees.

    DOI: 10.1038/s41598-020-79914-7

    PubMed

    researchmap

  • Pharmacokinetics and effects on clinical and physiological parameters following a single bolus dose of propofol in common marmosets (Callithrix jacchus). 査読 国際誌

    Kanako Muta, Takako Miyabe-Nishiwaki, Kenichi Masui, Isao Yajima, Tomoya Iizuka, Akihisa Kaneko, Ryohei Nishimura

    Journal of veterinary pharmacology and therapeutics   44 ( 1 )   18 - 27   2021年1月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The objectives of this study were (a) to establish a population pharmacokinetic model and (b) to investigate the clinical and physiological effects of a single bolus dose of propofol in common marmosets. In Study 1, pharmacokinetic analysis was performed in six marmosets under sevoflurane anaesthesia. 8 mg/kg of propofol was administrated at a rate of 4 mg kg-1  min-1 . Blood samples were collected 2, 5, 15, 30, 60, 90, 120 or 180 min after starting propofol administration. Plasma concentration was measured, and population pharmacokinetic modelling was performed. A two-compartment model was selected as the final model. The population pharmacokinetic parameters were as follows: V1  = 1.14 L, V2  = 77.6 L, CL1  = 0.00182 L/min, CL2  = 0.0461 L/min. In Study 2, clinical and physiological parameters were assessed and recorded every 2 min after 12 mg/kg of propofol was administrated at a rate of 4 mg kg-1  min-1 . Immobilization was sustained for 5 min following propofol administration without apparent bradycardia. While combination of propofol and sevoflurane caused apnoea in Study 1, apnoea was not observed following single administration of propofol in Study 2. These data provide bases for further investigation on intravenous anaesthesia using propofol in common marmosets.

    DOI: 10.1111/jvp.12905

    PubMed

    researchmap

  • Interpretation of laboratory tests for prevention of the SARS-CoV-2 transmission. 査読

    Kenichi Masui

    Journal of anesthesia   2020年11月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    With the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), medical providers should take care to prevent the transmission of SARS-CoV-2 in hospitals including super-spreading. Understanding super-spreading would be useful to reduce future transmission. Some publications have shown clusters of SARS-CoV-2 such as at choir practice and in hospitals. Aerosol can be considered as a primary transmission route. As SARS-CoV-2 stability in aerosol is similar to SARS-CoV-1 with the higher reproductive number of SARS-CoV-2 than SARS-CoV-1, another factor causes rapidly spread-out, e.g. a higher discharge ratio from infected people or a higher viral intake ratio to human body. A basic research suggests higher infectivity of SARS-CoV-2 in the nose than the peripheral lung. Universal masking would be important to prevent the exposure of SARS-CoV-2 droplet to uninfected people. To detect SARS-CoV-2 infection, laboratory tests such as reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assays are applied. Although sensitivity and specificity are provided for the ability of the test, positive or negative prediction values are useful to indicate the possiblity of infection or non-infection in clinical practice. We have to realize that the positive and negative prediction values depend on the sensitivity, specificity, and infection probability of the patient.

    DOI: 10.1007/s00540-020-02872-x

    PubMed

    researchmap

  • Risk prediction modeling based on a combination of initial serum biomarkers in myositis-associated interstitial lung disease. 査読 国際誌

    Takahisa Gono, Kenichi Masui, Naoshi Nishina, Yasushi Kawaguchi, Atsushi Kawakami, Kei Ikeda, Yohei Kirino, Yumiko Sugiyama, Yoshinori Tanino, Takahiro Nunokawa, Yuko Kaneko, Shinji Sato, Katsuaki Asakawa, Taro Ukichi, Shinjiro Kaieda, Taio Naniwa, Yutaka Okano, Masataka Kuwana

    Arthritis & rheumatology (Hoboken, N.J.)   73 ( 4 )   677 - 686   2020年10月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: To establish predictive models for mortality in patients with polymyositis/dermatomyositis (PM/DM)-associated interstitial lung disease (ILD) using a combination of initial serum biomarkers. METHODS: A multicenter JAMI cohort database of 497 incident cases of PM/DM-ILD was used as a derivation cohort, and 111 cases were additionally collected as a validation cohort. Risks for predicting all-cause mortality were identified by univariate and multivariable Cox regression analyses using candidate serum biomarkers as explanatory variables. The predictive models for mortality were generated in patients with and without anti-melanoma differentiation-associated gene 5 (MDA5) antibody, using a combination of risk factors. Cumulative survival rates were assessed using Kaplan-Meier analysis, and were compared between the subgroups with Breslow test. RESULTS: In a derivation cohort, C-reactive protein (CRP) and Krebs von den Lungen-6 (KL-6) were identified as independent risk factors for mortality in both anti-MDA5-positive and negative patients. We then developed a prediction model termed MCK (MDA5, CRP, and KL-6) model, identifying patients at low (<15%), moderate (15-50%), or high risk (≥50%) of mortality, based on the number of risk factors. The MCK model successfully differentiated cumulative survival rates in anti-MDA5-positive patients (P < 0.01 between low and moderate risk and P = 0.03 between moderate and high risk) and in anti-MDA5-negative patients (P < 0.001 between low and moderate risk). Utility of the MCK model was replicated in the validation cohort. CONCLUSION: The evidence-based risk prediction model using CRP and KL-6 combined with anti-MDA5 antibody might be useful for predicting prognosis in patients with PM/DM-ILD.

    DOI: 10.1002/art.41566

    PubMed

    researchmap

  • Propofol suppresses the His-ventricular conduction in paediatric patients. 査読 国際誌

    Mayuka Matsushima, Seishi Kimura, Atsuhiro Kitaura, Shinichi Hamasaki, Tatsushige Iwamoto, Takashi Mino, Kenichi Masui, Shinichi Nakao

    Journal of clinical pharmacy and therapeutics   46 ( 2 )   433 - 439   2020年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    WHAT IS KNOWN AND OBJECTIVE: Propofol is the most commonly used intravenous anaesthetic worldwide and is considered to be safe for all ages. However, there have been some reports that propofol induces severe atrioventricular (AV) blocks in humans and some studies demonstrated that propofol suppressed the cardiac conduction system in animals. A precise mechanism by which the block is induced has not been elucidated yet in humans. The objective of this study was to investigate the effects of propofol on the cardiac conduction system and the cardiac autonomic nervous balance in children. METHODS: We enrolled 23 paediatric patients (age: 6-15 years; males: 16, females: 7) who were scheduled to undergo radiofrequency catheter ablation (RFCA) under general anaesthesia. Anaesthesia was induced with 2 mg/kg propofol and 0.5 µg/kg/min remifentanil, and tracheal intubation was performed with the aid of 1 mg/kg rocuronium. Anaesthesia was maintained with 5-7 mg/kg/h propofol and 0.2 µg/kg/min remifentanil during the RFCA. After the completion of the RFCA, anaesthesia was further maintained with 5 mg/kg/h propofol and 0.2 µg/kg/min remifentanil for at least 10 min (LC: low propofol concentration state), followed by the injection of 2 mg/kg propofol and the infusion of 10 mg/kg/h propofol for 10 min (HC: high propofol concentration state). The sinus node recovery time (SNRT), sinoatrial conduction time (SACT), atrial-His (AH) interval and the His-ventricular (HV) interval were measured at the end of both the LC and HC. Cardiac autonomic regulation was simultaneously assessed based on heart rate variability. RESULTS AND DISCUSSION: Propofol significantly suppressed intrinsic cardiac HV conduction, but did not affect the SNRT, SACT or the AH interval. As HV blocks, which occur below the His bundle, are often life-threatening, the HV conduction delay may be a cause of severe AV blocks induced by propofol. Propofol directly suppressed parasympathetic nerve activity, and sympathetic nerve activity was also suppressed. WHAT IS NEW AND CONCLUSION: These results indicate that propofol suppresses the HV conduction and might help to elucidate the mechanism by which propofol causes lethal AV blocks.

    DOI: 10.1111/jcpt.13302

    PubMed

    researchmap

  • Severe hyponatremia with seizures and confirmed mild brain edema by hysteroscopic myomectomy: a case report. 査読 国際誌

    Haruko Okazaki, Norikazu Miura, Yuki Kashima, Ryoichi Miyashita, Katsunori Oe, Keiko Kawakami, Tetsuya Ishikawa, Kenichi Masui

    JA clinical reports   6 ( 1 )   74 - 74   2020年10月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Hyponatremia can be developed during hysteroscopic surgery with electrolyte-free irrigation fluid. We experienced severe hyponatremia with postoperative seizures and confirmed mild brain edema. CASE PRESENTATION: A quadragenarian female patient underwent a 2-h hysteroscopic myomectomy with electrolyte-free fluid for uterine distension under general anesthesia. Plasma sodium level of 84.1 mmol/L 100 min after the start of surgery indicated excessive absorption of the irrigation fluid. Acute severe hyponatremia was diagnosed with significant edema in the conjunctiva, lip, and extremities. She was treated with a continuous infusion of hypertonic saline. However, seizures and cerebral edema developed 7 h later. The patient recovered without neurological deficits at postoperative day 2. CONCLUSION: The electrolyte-free irrigation fluid can be absorbed rapidly during hysteroscopic surgery. Its interruption with hyponatremia should be considered against prolonged surgery. Especially under general anesthesia, caution should be exercised because the typical symptoms of hyponatremia such as nausea and confusion are blinded.

    DOI: 10.1186/s40981-020-00381-0

    PubMed

    researchmap

  • 小児のプロポフォール予測濃度の基礎 査読

    増井 健一

    日本小児麻酔学会誌   26 ( 1 )   100 - 104   2020年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本小児麻酔学会  

    researchmap

  • Suspected propofol infusion syndrome during normal targeted propofol concentration. 査読

    Taku Ichikawa, Keiko Okuyama, Kotoe Kamata, Kenichi Masui, Makoto Ozaki

    Journal of anesthesia   34 ( 4 )   619 - 623   2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    To this day, the pathophysiology and risk factors of propofol infusion syndrome (PRIS) remain unknown. Moreover, there is no widely accepted definition of PRIS, even though it is a potentially fatal condition. While many suspected cases of PRIS have been reported in both pediatric and adult populations, the actual propofol plasma concentration (Cp) has never been clarified. In this clinical report, we described the first suspected PRIS case in which the propofol Cp was measured 25 min after 226 min of propofol infusion (7.2 µg/mL), which was 12 times higher than the predicted value (0.6 µg/mL). In the presented case, we observed gradually progressive uncontrollable hypercapnia and tachycardia, followed by severe lactic acidosis during surgical anesthesia based on the target-controlled infusion of propofol. Levels of liver enzymes were slightly elevated which suggests little or no liver damage though propofol is mainly metabolized by the liver. Meanwhile, renal impairment, a common secondary feature of PRIS, occurred concomitantly when hypercapnia and metabolic acidosis were manifested. In this case, low or delayed propofol clearance might have been a triggering factor causing severe lactic acidosis.

    DOI: 10.1007/s00540-020-02773-z

    PubMed

    researchmap

  • Individual pharmacometric analysis for sugammadex reversal and re-administration of neuromuscular blockade. 査読

    Yuki Kashima, Kenichi Masui

    Journal of anesthesia   2020年7月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Sugammadex is an innovative reversal agent for neuromuscular blockade (NMB) induced by rocuronium. Although there is a case that re-paralysis is necessary after sugammadex administration, limited reports can be found on the sugammadex dosage for reversal from profound paralysis after induction and immediate re-paralysis following such reversal in detail. We experienced a case in which NMB reversal was required in a short period after paralysis for induction due to the discovery of anisocoria. We successfully re-induced general anesthesia with tracheal intubation soon after. To examine the validity of the dosing, we performed a pharmacometric analysis. A pharmacokinetic-pharmacodynamic model was developed for the patient based on a published pharmacokinetic-pharmacodynamic model for rocuronium and sugammadex. The developed model appropriately describes the train of four ratio observed. In this case, the dose of approximately 8 mg/kg sugammadex but not the conventional dose of 16 mg/kg would be enough for immediate reversal after induction. For the re-paralysis 30 min after NMB reversal, not 1.4 mg/kg but 2.2 mg/kg rocuronium was an adequate dose. Taking individual differences including given dose and time intervals in consideration, NMB monitoring should be used to determine the necessary dose of rocuronium and sugammadex in such situations.

    DOI: 10.1007/s00540-020-02824-5

    PubMed

    researchmap

  • Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. 査読 国際誌

    Naoshi Nishina, Shinji Sato, Kenichi Masui, Takahisa Gono, Masataka Kuwana

    RMD open   6 ( 2 )   2020年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: To investigate whether the onset of polymyositis (PM)/dermatomyositis (DM)-associated interstitial lung disease (ILD) is influenced by season and residence in the context of myositis-specific autoantibodies. METHODS: For patients with PM/DM-associated ILD enrolled in a multicentre cohort, 365 and 481 patients were eligible for seasonal and geographical analysis, respectively, based on the availability of reliable clinical information. The patients were divided into three groups: (1) anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive patients, (2) anti-aminoacyl tRNA synthetase (anti-ARS) antibody-positive patients and (3) patients negative for those antibodies. Seasonality was assessed by the Rayleigh test. Distance from residence to the nearest waterfront was measured on Google Map and was compared between groups by the exact Wilcoxon rank-sum test. RESULTS: In anti-MDA5-positive patients, the disease developed more frequently in October-March (p=0.03), whereas a seasonal relationship was not found in the remaining two patient groups. Residence at disease onset in anti-MDA5-positive patients was significantly closer to the waterfront, especially to freshwater, compared with that in anti-ARS-positive or anti-MDA5-/ARS-negative patients (p=0.003 and 0.006, respectively). CONCLUSIONS: Anti-MDA5-associated ILD occurred predominantly from October to March in individuals residing near freshwater, suggesting an environmental influence on the onset of this disease subset.

    DOI: 10.1136/rmdopen-2020-001202

    PubMed

    researchmap

  • Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia!! 査読

    Kenichi Masui

    Journal of anesthesia   2020年3月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語  

    DOI: 10.1007/s00540-020-02755-1

    PubMed

    researchmap

  • The efficacy of acute normovolemic hemodilution for preventing perioperative allogeneic blood transfusion in gynecological cancer patients. 査読 国際誌

    Junichi Saito, Kenichi Masui, Satoko Noguchi, Kishiko Nakai, Yoshiko Tamai, Yoko Midorikawa, Hirotaka Kinoshita, Noriko Mikami, Masato Kitayama, Hiroshi Hashimoto, Kazuyoshi Hirota

    Journal of clinical anesthesia   60   42 - 43   2020年3月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語  

    DOI: 10.1016/j.jclinane.2019.08.025

    PubMed

    researchmap

  • Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study. 査読 国際誌

    Yuko Kaneko, Takahiro Nunokawa, Yoshinori Taniguchi, Yukie Yamaguchi, Takahisa Gono, Kenichi Masui, Atsushi Kawakami, Yasushi Kawaguchi, Shinji Sato, Masataka Kuwana

    Rheumatology (Oxford, England)   59 ( 1 )   112 - 119   2020年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: To clarify the incidence, risk factors, and impact of malignancy in patients with PM/DM-associated interstitial lung disease (ILD). METHODS: This study used data from 497 patients with PM/DM-associated ILD enrolled in a multicentre, retrospective and prospective cohort of incident cases. Cancer-associated myositis (CAM) was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic and clinical information was recorded at the time of diagnosis, and data about the occurrence of mortality and malignancy was collected. RESULTS: CAM was identified in 32 patients with PM/DM-associated ILD (6.4%). Patients with CAM were older (64 vs 55 years, P < 0.001), presented with arthritis less frequently (24% vs 49%, P = 0.01), and showed a lower level of serum Krebs von den Lungen-6 (687 vs 820 IU/l, P = 0.03) than those without CAM. The distribution of myositis-specific autoantibodies, including anti-melanoma differentiation-associated gene 5, anti-aminoacyl tRNA synthetase, and anti-transcriptional intermediary factor 1-γ antibodies, did not differ between the groups. Survival analysis demonstrated that CAM patients had a poorer survival than non-CAM patients (P = 0.006), primarily due to excess deaths by concomitant malignancy, while mortality due to ILD-related respiratory failure was similar between the groups (P = 0.51). CONCLUSION: Concomitant malignancy can occur in patients with PM/DM-associated ILD, and has significant impact on mortality. Older age, lack of arthritis, and a lower level of serum Krebs von den Lungen-6 at diagnosis are predictors of concomitant malignancy.

    DOI: 10.1093/rheumatology/kez238

    PubMed

    researchmap

  • Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease. 査読 国際誌

    Shinjiro Kaieda, Takahisa Gono, Kenichi Masui, Naoshi Nishina, Shinji Sato, Masataka Kuwana

    PloS one   15 ( 6 )   e0234523   2020年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: Surfactant protein D (SP-D) is considered a serum biomarker of various forms of interstitial lung disease (ILD). In this study, we examined the utility of SP-D as a predictive biomarker for mortality in patients with ILD associated with polymyositis/dermatomyositis (PM/DM) using large-scale multicentre cohort data. METHODS: We enrolled 381 patients with incident PM/DM-associated ILD in a multicentre retrospective cohort based on the availability of serum SP-D at the baseline. Demographic and clinical characteristics as well as the presence of autoantibodies to melanoma differentiation-associated gene 5 (MDA5) and aminoacyl tRNA synthetase were measured at the time of diagnosis, and follow-up survival data were collected prospectively. RESULTS: Seventy-eight patients died during the median observation period of 18 months, and the majority of patients died of ILD. The SP-D levels at baseline were significantly lower (P = 0.02) in a non-survivor subset than in a survivor subset among the entire enrolled patients. However, the SP-D levels were higher in the non-survivor subset than in the survivor subset based on the stratification by anti-MDA5-positive, anti-ARS-positive and, double-negativity, although there was an only statistically significant difference (P = 0.01) in the double-negative group. Surprisingly, the SP-D levels were within the upper limit of normal, 110 ng/mL, in 54 (87%) of 62 anti-MDA5-positive patients who died. In the double-negative group, the mortality rates were significantly higher (P = 0.002) in a subset with SP-D ≥127.6 ng/mL, the cut-off value for mortality calculated by the receiver operating characteristic curve, than the other subset. All of patients with SP-D <127.6 ng/mL survived. CONCLUSION: Serum SP-D levels behave differently among patients with stratified by anti-MDA5 antibody, anti-ARS antibody and both negativity in PM/DM-associated ILD. Its use in clinical practice should be applied with caution on the basis of the presence or absence of anti-MDA5 antibody or anti-ARS antibody.

    DOI: 10.1371/journal.pone.0234523

    PubMed

    researchmap

  • Rocuronium pharmacodynamic models for published five pharmacokinetic models: age and sex are covariates in pharmacodynamic models. 査読

    Kenichi Masui, Sayaka Ishigaki, Atsuko Tomita, Hiroshi Otake

    Journal of anesthesia   32 ( 5 )   709 - 716   2018年10月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00540-018-2543-3

    Web of Science

    PubMed

    researchmap

  • Comparison of plasma propofol concentration for apnea, response to mechanical ventilation, and airway device between endotracheal tube and supraglottic airway device in Beagles. 査読

    Tomoya Iizuka, Kenichi Masui, Hideko Kanazawa, Ryohei Nishimura

    The Journal of veterinary medical science   80 ( 9 )   1420 - 1423   2018年9月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The relationships between propofol plasma concentrations and the pharmacodynamic endpoints may differ according to a type of airway device. To clarify these relationships in different airway devices would be useful to avoid the complication such as apnea and intraoperative awareness. The aim of this study was to investigate the influence of difference of airway device on propofol requirement during maintenance of anesthesia in dogs. We compared the influence of airway devices on the plasma propofol concentrations for apnea, response to mechanical ventilation, and response to airway device between endotracheal tube (ETT) and supraglottic airway device (SGAD) in Beagles. The pharmacodynamic effects were repeatedly assessed at varying propofol concentrations. The plasma concentrations (mean ± SD) of propofol in the ETT and SGAD groups were 10.2 ± 1.8 and 10.9 ± 2.4 µg/ml for apnea (P=0.438), 7.9 ± 1.2 and 7.4 ± 1.5 µg/ml for response to mechanical ventilation (P=0.268), and 5.2 ± 0.7 and 5.4 ± 1.5 µg/ml for response to airway device (P=0.580), respectively. Required propofol concentration during maintenance of anesthesia may be similar between ETT and SGAD. Without moderate to strong stimuli such as airway device insertion or painful stimulation during surgery, the type of airway device may have little impact on required propofol concentration during maintenance of anesthesia in dogs.

    DOI: 10.1292/jvms.17-0468

    PubMed

    researchmap

  • Calcineurin Inhibitor for the Treatment of Myositis-Associated Interstitial Lung Disease: Comparison between Cyclosporine and Tacrolimus 査読

    Gono Takahisa, Masui Kenichi, Nishina Naoshi, Sato Shinji, Kuwana Masataka

    ARTHRITIS & RHEUMATOLOGY   70   2018年9月

  • Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. 査読 国際誌

    Shinji Sato, Kenichi Masui, Naoshi Nishina, Yasushi Kawaguchi, Atsushi Kawakami, Maasa Tamura, Kei Ikeda, Takahiro Nunokawa, Yoshinori Tanino, Katsuaki Asakawa, Yuko Kaneko, Takahisa Gono, Taro Ukichi, Shinjiro Kaieda, Taio Naniwa, Masataka Kuwana

    Rheumatology (Oxford, England)   57 ( 7 )   1212 - 1221   2018年7月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/rheumatology/key060

    Web of Science

    Scopus

    PubMed

    researchmap

  • Size of uterine leiomyoma is a predictor for massive haemorrhage during caesarean delivery. 査読 国際誌

    Kiguna Sei, Kenichi Masui, Hidenori Sasa, Kenichi Furuya

    European journal of obstetrics, gynecology, and reproductive biology   223   60 - 63   2018年4月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.ejogrb.2018.02.014

    Web of Science

    PubMed

    researchmap

  • Clinical Utility of Intraoperative Motor-Evoked Potential Monitoring to Prevent Postoperative Spinal Cord Injury in Thoracic and Thoracoabdominal Aneurysm Repair: An Audit of the Japanese Association of Spinal Cord Protection in Aortic Surgery Database. 査読 国際誌

    Kenji Yoshitani, Kenichi Masui, Masahiko Kawaguchi, Mikito Kawamata, Manabu Kakinohana, Shinya Kato, Kyoko Hasuwa, Michiaki Yamakage, Yusuke Yoshikawa, Kimitoshi Nishiwaki, Tadashi Aoyama, Yoshimi Inagaki, Kazumasa Yamasaki, Mishiya Matsumoto, Kazuyoshi Ishida, Atsuo Yamashita, Katsuhiro Seo, Shinichi Kakumoto, Hironobu Hayashi, Yuu Tanaka, Satoshi Tanaka, Takashi Ishida, Hiroyuki Uchino, Takayasu Kakinuma, Yoshitsugu Yamada, Yoshiteru Mori, Shunsuke Izumi, Kunihiro Nishimura, Michikazu Nakai, Yoshihiko Ohnishi

    Anesthesia and analgesia   126 ( 3 )   763 - 768   2018年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1213/ANE.0000000000002749

    Web of Science

    PubMed

    researchmap

  • Propofol-fentanyl interaction in Beagles - Apnea, response to mechanical ventilation, endotracheal tube, and tetanic stimulation 査読

    T. Iizuka, K. Masui, T. Miyabe-Nishiwaki, H. Kanazawa, R. Nishimura

    RESEARCH IN VETERINARY SCIENCE   115   34 - 42   2017年12月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.rvsc.2017.01.021

    Web of Science

    researchmap

  • Predictive Modeling of Mortality in Polymyositis/Dermatomyositis Patients with Interstitial Lung Disease Based on Combination of Serum Myositis-Specific Autoantibodies and Conventional Biomarkers 査読

    Takahisa Gono, Kenichi Masui, Yasushi Kawaguchi, Kei Ikeda, Atsushi Kawakami, Maasa Tamura, Yoshinori Tanino, Takahiro Nunokawa, Yuko Kaneko, Shinji Sato, Katsuaki Asakawa, Naoshi Nishina, Masataka Kuwana

    ARTHRITIS & RHEUMATOLOGY   69   2017年10月

     詳細を見る

    記述言語:英語  

    Web of Science

    researchmap

  • Influence of maternal remifentanil concentration on fetal-to-maternal ratio in pregnant ewes. 査読

    Masaki Sato, Kenichi Masui, Borjigin Sarentonglaga, Mio Yamaguchi, Rika Fukumori, Yoshikazu Nagao, Haruhiko Sago, Hiroyuki Sumikura

    Journal of anesthesia   31 ( 4 )   517 - 522   2017年8月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00540-017-2332-4

    Web of Science

    PubMed

    researchmap

  • In Reply. 査読 国際誌

    Kenichi Masui, Sayako Itakura

    Anesthesiology   126 ( 5 )   986 - 986   2017年5月

     詳細を見る

  • In Response. 査読 国際誌

    Kenichi Masui, Sayaka Ishigaki

    Anesthesia and analgesia   124 ( 2 )   695 - 696   2017年2月

     詳細を見る

  • Influence of preoperative oral rehydration on arterial plasma rocuronium concentrations and neuromuscular blocking effects: A randomised controlled trial. 査読 国際誌

    Sayaka Ishigaki, Takahiro Ogura, Ayana Kanaya, Yu Miyake, Kenichi Masui, Tomiei Kazama

    European journal of anaesthesiology   34 ( 1 )   16 - 21   2017年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/EJA.0000000000000526

    Web of Science

    PubMed

    researchmap

  • Systematic review of motor evoked potentials monitoring during thoracic and thoracoabdominal aortic aneurysm open repair surgery: a diagnostic meta-analysis. 査読

    Yuu Tanaka, Masahiko Kawaguchi, Yoshinori Noguchi, Kenji Yoshitani, Mikito Kawamata, Kenichi Masui, Takeo Nakayama, Yoshitugu Yamada

    Journal of anesthesia   30 ( 6 )   1037 - 1050   2016年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00540-016-2242-x

    Web of Science

    PubMed

    researchmap

  • Influence of Season and Residential Environment on Development of Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis with Interstitial Lung Disease 査読

    Naoshi Nishina, Shinji Sato, Yasushi Kawaguchi, Atsushi Kawakami, Maasa Tamura, Kei Ikeda, Takahiro Nunokawa, Yoshinori Tanino, Katsuaki Asakawa, Yuko Kaneko, Takahisa Gono, Kenichi Masui, Masataka Kuwana

    ARTHRITIS & RHEUMATOLOGY   68   2016年10月

     詳細を見る

    記述言語:英語  

    Web of Science

    researchmap

  • Initial Predictors of Short-Term Poor Survival Rates in Patients with Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease 査読

    Shinji Sato, Kenichi Masui, Naoshi Nishina, Yasushi Kawaguchi, Atsushi Kawakami, Maasa Tamura, Kei Ikeda, Takahiro Nunokawa, Yoshinori Tanino, Katsuaki Asakawa, Yuko Kaneko, Takahisa Gono, Masataka Kuwana

    ARTHRITIS & RHEUMATOLOGY   68   2016年10月

     詳細を見る

    記述言語:英語  

    Web of Science

    researchmap

  • The predictive ability of six pharmacokinetic models of rocuronium developed using a single bolus: evaluation with bolus and continuous infusion regimen. 査読

    Tomoki Sasakawa, Kenichi Masui, Tomiei Kazama, Hiroshi Iwasaki

    Journal of anesthesia   30 ( 4 )   620 - 7   2016年8月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00540-016-2174-5

    Web of Science

    PubMed

    researchmap

  • Rapid Infusion of Hydroxyethyl Starch 70/0.5 but not Acetate Ringer's Solution Decreases the Plasma Concentration of Propofol during Target-controlled Infusion. 査読 国際誌

    Sayako Itakura, Kenichi Masui, Tomiei Kazama

    Anesthesiology   125 ( 2 )   304 - 12   2016年8月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/ALN.0000000000001184

    Web of Science

    PubMed

    researchmap

  • The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. 査読 国際誌

    Yumiko Takaenoki, Kenichi Masui, Yutaka Oda, Tomiei Kazama

    Anesthesia and analgesia   123 ( 1 )   74 - 81   2016年7月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1213/ANE.0000000000001317

    Web of Science

    PubMed

    researchmap

  • Saline Flush After Rocuronium Bolus Reduces Onset Time and Prolongs Duration of Effect: A Randomized Clinical Trial. 査読 国際誌

    Sayaka Ishigaki, Kenichi Masui, Tomiei Kazama

    Anesthesia and analgesia   122 ( 3 )   706 - 11   2016年3月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1213/ANE.0000000000001094

    Web of Science

    PubMed

    researchmap

  • Pulse wave transit time measurements of cardiac output in patients undergoing partial hepatectomy: a comparison of the esCCO system with thermodilution. 査読 国際誌

    Masato Tsutsui, Yoshiyuki Araki, Kenichi Masui, Tomiei Kazama, Yoshihiro Sugo, Thomas L Archer, Gerard R Manecke Jr

    Anesthesia and analgesia   117 ( 6 )   1307 - 12   2013年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1213/ANE.0b013e3182a44c87

    Web of Science

    PubMed

    researchmap

  • Utility Of Autoantibody Testing For Predicting Risk Of Pulmonary Arterial Hypertension: A Retrospective Analysis In Routine Autoantibody Laboratory 査読

    Masataka Kuwana, Yuichiro Shirai, Hidekata Yasuoka, Tsutomu Takeuchi, Kenichi Masui

    ARTHRITIS AND RHEUMATISM   65   S1098 - S1099   2013年10月

     詳細を見る

    記述言語:英語  

    Web of Science

    researchmap

  • Evaluation of the predictive performance of a pharmacokinetic model for propofol in Japanese macaques (Macaca fuscata fuscata) 査読

    T. Miyabe-Nishiwaki, K. Masui, A. Kaneko, K. Nishiwaki, T. Nishio, H. Kanazawa

    Journal of Veterinary Pharmacology and Therapeutics   36 ( 2 )   169 - 173   2013年4月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/j.1365-2885.2012.01404.x

    Scopus

    PubMed

    researchmap

  • Neonatal desflurane exposure induces more robust neuroapoptosis than do isoflurane and sevoflurane and impairs working memory. 査読 国際誌

    Mitsuyoshi Kodama, Yasushi Satoh, Yukiko Otsubo, Yoshiyuki Araki, Ryuji Yonamine, Kenichi Masui, Tomiei Kazama

    Anesthesiology   115 ( 5 )   979 - 91   2011年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/ALN.0b013e318234228b

    Web of Science

    PubMed

    researchmap

  • Effect of fentanyl on ischemic depolarization and ischemic neuronal damage of hippocampal CA1 in the gerbil. 査読

    Kensuke Shiraishi, Yoshimasa Takeda, Kenichi Masui, Hideki Taninishi, Toshihiro Sasaki, Tetsuya Danura, Kiyoshi Morita

    Journal of anesthesia   25 ( 4 )   540 - 8   2011年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00540-011-1143-2

    Web of Science

    PubMed

    researchmap

  • Awareness during anesthesia: the results of a questionnaire survey in Japan. 査読

    Yasuhiro Morimoto, Yuko Nogami, Kaori Harada, Tsunehisa Tsubokawa, Kenichi Masui

    Journal of anesthesia   25 ( 1 )   72 - 7   2011年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00540-010-1050-y

    Web of Science

    PubMed

    researchmap

  • Hypnotic effects and pharmacokinetics of a single bolus dose of propofol in Japanese macaques (Macaca fuscata fuscata). [corrected]. 査読 国際誌

    Takako Miyabe-Nishiwaki, Kenichi Masui, Akihisa Kaneko, Koki Nishiwaki, Etsuko Shimbo, Hideko Kanazawa

    Veterinary anaesthesia and analgesia   37 ( 6 )   501 - 10   2010年11月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/j.1467-2995.2010.00564.x

    Web of Science

    PubMed

    researchmap

  • The performance of compartmental and physiologically based recirculatory pharmacokinetic models for propofol: a comparison using bolus, continuous, and target-controlled infusion data. 査読 国際誌

    Kenichi Masui, Richard N Upton, Anthony G Doufas, Johan F Coetzee, Tomiei Kazama, Eric P Mortier, Michel M R F Struys

    Anesthesia and analgesia   111 ( 2 )   368 - 79   2010年8月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1213/ANE.0b013e3181bdcf5b

    Web of Science

    PubMed

    researchmap

  • Effects of a short-acting [beta]1 receptor antagonist landiolol on hemodynamics and tissue injury markers in patients with subarachnoid hemorrhage undergoing intracranial aneurysm surgery. 査読 国際誌

    Masahiko Kawaguchi, Kouji Utada, Kenji Yoshitani, Hiroyuki Uchino, Yoshimasa Takeda, Kenichi Masui, Takefumi Sakabe

    Journal of neurosurgical anesthesiology   22 ( 3 )   230 - 9   2010年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/ANA.0b013e3181d0c2e4

    Web of Science

    PubMed

    researchmap

  • Early phase pharmacokinetics but not pharmacodynamics are influenced by propofol infusion rate. 査読 国際誌

    Kenichi Masui, Marimo Kira, Tomiei Kazama, Satoshi Hagihira, Eric P Mortier, Michel M R F Struys

    Anesthesiology   111 ( 4 )   805 - 17   2009年10月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/ALN.0b013e3181b799c1

    Web of Science

    PubMed

    researchmap

  • [Pharmacokinetic simulations of remifentanil]. 査読

    Kenichi Masui, Tomiei Kazama

    Masui. The Japanese journal of anesthesiology   56 ( 11 )   1287 - 95   2007年11月

     詳細を見る

    担当区分:筆頭著者   記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    Remifentanil has short half-lives: the values of alpha and beta decay are about 2 and 15 min, respectively. Therefore, the time for remifentanil concentration to reach its steady state concentration (Css) is shorter than those of other anesthetic drugs such as propofol and fentanyl. The Css and the time course of plasma concentration as well as effect-site concentration (Ce) during the continuous infusion of remifentanil could be helpful in our clinical practice. Css is strongly affected by weight and age with Minto's pharmacokinetic parameters of remifentanil. Css increases by a factor of 1.8 when the weight doubles, and Css in a 75-year-old is 1.5 times higher than Css in a 25-year-old. We tried to simulate the time courses of remifentanil Ce and fentanyl Ce during induction, maintenance, and emergence phases of anesthesia. Because of the short half-lives, remifentanil concentration could be well-controlled. However, remifentanil concentration does not reach the Css immediately with constant rate infusion. For example, it will take about 5 min for remifentanil effect-site concentration to decrease from Css to a half of Css. It is considered that anesthetic management with remifentanil is superior to that without it.

    PubMed

    researchmap

  • On-line monitoring of end-tidal propofol concentration in anesthetized patients. 査読 国際誌

    Akira Takita, Kenichi Masui, Tomiei Kazama

    Anesthesiology   106 ( 4 )   659 - 64   2007年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/01.anes.0000264745.63275.59

    Web of Science

    PubMed

    researchmap

  • [Comparison of pentazocine and fentanyl in total intravenous anesthesia using propofol]. 査読

    Akihiko Nonaka, Satomi Suzuki, Fumiaki Abe, Kenichi Masui

    Masui. The Japanese journal of anesthesiology   55 ( 8 )   983 - 7   2006年8月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Pentazocine may be an alternative for fentanyl during total intravenous anesthesia (TIVA) using propofol. The authors compared the efficacy and safety of pentazocine for analgesics in TIVA using propofol. METHODS: Eighty-nine patients scheduled for mastectomy were analyzed retrospectively. Patients were classified into two groups by used analgesics; pentazocine (Group P, n = 34) and fentanyl (Group F, n = 55). Anesthesia was induced with propofol, using target controlled infusion method, and ketamine 20-50 mg, and was maintained with propofol infusion and increments of fentanyl or single dose of pentazocine with 40% oxygen in air. Postoperative pain was assessed using a visual analogue pain scale (VAS). RESULTS: There were no differences in the patient background between both groups. Systolic as well as diastolic blood pressure and heart rate were not different between both groups during surgery. The maintenance dose of propofol was not different between the two groups. Awakening time in about 80% of patients was within 15 minutes and is not different between the two groups. There were no differences between the two groups regarding VAS. There are no severe complications. Incidence of nausea and vomiting was not different between the two groups. CONCLUSIONS: The results suggest that pentazocine would provide a stable hemodynamic state, rapid recovery and an effective postoperative pain relief to the same degree as with fentanyl in TIVA with propofol.

    PubMed

    researchmap

  • Isoflurane and sevoflurane during reperfusion prevent recovery from ischaemia in mitochondrial KATP channel blocker pretreated hearts 査読

    K. Masui, S. Kashimoto, A. Furuya, T. Oguchi

    European Journal of Anaesthesiology   23 ( 2 )   123 - 129   2006年2月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1017/S0265021505002024

    Scopus

    PubMed

    researchmap

  • [Refractory generalized convulsions in a patient undergoing brain tumor resection during propofol anesthesia]. 査読

    Hisashi Fukushima, Tadahiko Ishiyama, Takeshi Oguchi, Kenichi Masui, Takashi Matsukawa, Teruo Kumazawa

    Masui. The Japanese journal of anesthesiology   53 ( 6 )   691 - 2   2004年6月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    Propofol has been used to treat convulsions, while the drug is known to induce convulsions. We described a case of generalized convulsions during brain tumor resection under propofol anesthesia. A 24-year-old man was scheduled to undergo brain tumor resection. He had no history of epilepsy. Anesthesia was induced and maintained with propofol and fentanyl. During the craniotomy, the patient developed generalized convulsions. Diazepam, thiamylal, and phenytoin were given intravenously and the seizure activity resolved. Generalized convulsions recurred three times during the operation. Postoperative course was uneventful. On the 16 th postoperative day, the patient underwent ventriculoperitoneal shunt under general anesthesia using sevoflurane, nitrous oxide and oxygen. Convulsions were not noted intra- and postoperatively. Because convulsions did not occur during sevoflurane anesthesia and the patient had no history of epilepsy, propofol may have induced a generalized convulsions on the first operation.

    PubMed

    researchmap

  • Sevoflurane reduces dysrhythmias during reperfusion in the working rat heart 査読

    T. Oguchi, S. Kashimoto, T. Yamaguchi, K. Masui, T. Kumazawa

    Journal of Anesthesia   15 ( 1 )   22 - 28   2001年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s005400170047

    Scopus

    researchmap

▼全件表示

書籍等出版物

  • 麻酔科研修ノート

    増井 健一( 担当: 共著 範囲: 麻酔関連偶発症例調査)

    診断と治療社  2024年12月  ( ISBN:9784787826343

     詳細を見る

    総ページ数:xxviii, 718p   記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔科学レビュー2024 : 最新主要文献とガイドラインでみる

    増井 健一( 担当: 共著 範囲: 新しい全身麻酔薬レミマゾラム)

    総合医学社  2024年6月  ( ISBN:9784883784820

     詳細を見る

    総ページ数:359p   記述言語:日本語  

    CiNii Books

    researchmap

    その他リンク: https://mol.medicalonline.jp/library/ebooks/detail?id=11083

  • 臨床麻酔薬理学書

    増井 健一( 担当: 共著 範囲: 1章薬物動態学、2章薬力学)

    中山書店  2023年12月  ( ISBN:9784521750699

     詳細を見る

    総ページ数:xii, 379p   記述言語:日本語  

    CiNii Books

    researchmap

  • 理解して使いこなす麻酔科機器 : モニター・ICU機器・ペースメーカー

    増井 健一( 担当: 共著 範囲: 呼気プロポフォール濃度分析)

    文光堂  2023年11月  ( ISBN:9784830628580

     詳細を見る

    総ページ数:212p   記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔科学レビュー2023 : 最新主要文献とガイドラインでみる

    増井 健一( 担当: 共著 範囲: 新しい全身麻酔薬レミマゾラム)

    総合医学社  2023年5月  ( ISBN:9784883784721

     詳細を見る

    総ページ数:357p   記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔科学レビュー 2022: 最新主要文献とガイドラインでみる

    増井 健一( 担当: 共著 範囲: 新しい全身麻酔薬レミマゾラム)

    総合医学社  2022年6月  ( ISBN:9784883787487

     詳細を見る

    総ページ数:335p   記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔における気道管理の手技と知識を知る

    増井 健一( 担当: 共著 範囲: 第6章-1 麻酔導入法の種類)

    日本医事新報社  2022年6月  ( ISBN:9784784959365

     詳細を見る

  • レミマゾラムQ&A : 明日からの臨床麻酔が広がる

    増井 健一( 担当: 共著 範囲: Q9 覚醒する効果部位濃度はどの程度でしょうか? レミマゾラムのcontext-sensitive decrement timeについても教えてください;Q17 麻薬性鎮痛薬の併用方法は?プロポフォールと同様でよいのでしょうか?)

    克誠堂出版  2022年5月  ( ISBN:9784771905627

     詳細を見る

    総ページ数:xi, 305p   記述言語:日本語  

    CiNii Books

    researchmap

  • 読んでおきたい麻酔科学論文

    増井 健一( 担当: 共著 範囲: 第2章 静脈麻酔)

    克誠堂出版  2022年2月 

     詳細を見る

  • 神経麻酔最前線 すべては患者の機能維持・向上のために

    増井 健一( 担当: 共著 範囲: 5. ベンゾジアゼピン系薬物; column 3 新薬レミマゾラムのこの領域における可能性)

    中外医学社  2021年6月  ( ISBN:9784498055483

     詳細を見る

  • 麻酔科学レビュー2021

    増井 健一( 担当: 共著 範囲: 新しい全身麻酔薬レミマゾラム)

    総合医学社  2021年6月  ( ISBN:9784883787425

     詳細を見る

  • 高齢者麻酔のポイント50

    増井 健一( 担当: 共著 範囲: 若年・壮年と比べた高齢者の薬物動態・薬力学の特徴について教えてください)

    克誠堂出版  2021年6月  ( ISBN:9784771905504

     詳細を見る

  • 新臨床麻酔スタンダード

    増井 健一( 担当: 共著 範囲: 新しい全身麻酔薬レミマゾラム)

    克誠堂出版  2020年5月  ( ISBN:9784771905337

     詳細を見る

    総ページ数:vii, 434p   記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔・集中治療とテクノロジー2019

    ( 担当: 共著 範囲: AI・人工知能 EXPO で見つけたテクノロジー)

    日本麻酔・集中治療テクノロジー学会  2020年3月 

     詳細を見る

  • 一歩進んだ麻酔管理 : 常識は常に真実か?

    増井 健一( 担当: 共著 範囲: 全身麻酔薬と麻薬の相乗作用; BISモニターは術中覚醒を予防しない?)

    克誠堂出版  2019年5月  ( ISBN:9784771905160

     詳細を見る

    総ページ数:xiv, 294p   記述言語:日本語  

    CiNii Books

    researchmap

  • 医学系研究、論文投稿上のQ&A : すべての医療従事者が知りたい!

    増井 健一( 担当: 共著 範囲: Q33 研究対象者数はなぜ事前に決める必要があるのですか?; Q34 研究対象者数はどのように決めるのですか?; Q35 研究開始前に決めておくべき統計事項は何ですか?; Q37 データは何を収集・記録・保存しておく必要がありますか?; Q39 データはどう解析すればよいですか?)

    日本医事新報社  2017年8月  ( ISBN:9784784946358

     詳細を見る

    総ページ数:173p   記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔偶発症A to Z

    増井 健一( 担当: 共著 範囲: プロポフォールの有害作用; 麻薬性オピオイド全身投与による呼吸抑制,過鎮静,悪心・嘔吐,瘙痒感,尿閉,便秘)

    文光堂  2017年6月  ( ISBN:9784830628450

     詳細を見る

    総ページ数:15, 660 p   記述言語:日本語  

    CiNii Books

    researchmap

  • Total Intravenous Anesthesia and Target Controlled Infusions: A Comprehensive Global Anthology

    Kenichi Masui( 担当: 共著 範囲: How to Select a PK/PD Model)

    Springer International Publishing  2017年3月 

     詳細を見る

    ISBN: 9783319476060(hard cover)

    researchmap

  • エビデンスで読み解く小児麻酔

    増井 健一( 担当: 共著 範囲: 小児の発達薬理学とPK・PD)

    克誠堂出版  2016年11月  ( ISBN:9784771904729

     詳細を見る

    総ページ数:vii, 286p   記述言語:日本語  

    CiNii Books

    researchmap

  • 臨床の疑問に答える静脈麻酔Q&A99

    増井 健一( 担当: 共著 範囲: Q28 麻酔維持中のプロポフォール目標濃度は一定でよいのでしょうか?; column薬物血中濃度に対する心拍出量の影響; Q29 レミフェンタニルとフェンタニルの併用時に効果部位濃度を加算して考えてよいのでしょうか?; Q82 生理学的モデルとは何ですか?; Q84 コンパートメントモデルの各パラメータ(Vi,kijなど)の意味を教えてください; Q89 Context-sensitive half-time(CSHT)とは何を表すものですか?; Q90 鎮痛薬と鎮静薬の相互作用について教えてください; Q91 Response Surfaceの見方について教えてください; Q92 薬物動態モデルを利用した濃度予測はあらゆる患者に適用できるのでしょうか?; Q93 薬物動態モデルの精度はどのような方法で評価するのでしょうか?; Q94 LBMが使われている薬物動態モデルの問題を教えてください; column3-コンパートメントモデルの微分方程式; column薬物動態モデル・薬力学的モデルの作成方法; 付録② 薬物動態モデル一覧; 付録③ 静脈麻酔を理解するための用語集)

    羊土社  2015年11月  ( ISBN:9784758111140

     詳細を見る

    総ページ数:243p   記述言語:日本語  

    CiNii Books

    researchmap

  • 鎮静と術中覚醒

    増井 健一( 担当: 共著 範囲: Isolated Forearm Technique)

    真興交易医書出版部  2015年10月  ( ISBN:9784880039008

     詳細を見る

    総ページ数:132p   記述言語:日本語  

    CiNii Books

    researchmap

  • 周術期管理の謎22

    増井 健一( 担当: 共著 範囲: レミフェンタニルの1μg/kg/min の投与に意味はあるのか?)

    克誠堂出版  2015年6月  ( ISBN:9784771904460

     詳細を見る

    総ページ数:vii, 216p   記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔科医のための周術期の薬物使用法

    増井 健一( 担当: 共著 範囲: レミフェンタニル;フェンタニル)

    中山書店  2015年5月  ( ISBN:9784521737126

     詳細を見る

    総ページ数:523p   記述言語:日本語  

    CiNii Books

    researchmap

  • 改訂版 麻酔科薬剤ノート : 周術期の麻酔・救急対応薬の使用のポイント

    増井 健一( 担当: 共著 範囲: 降圧薬/冠血管拡張薬)

    羊土社  2014年11月  ( ISBN:9784758111119

     詳細を見る

    総ページ数:308p   記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔科医のための知っておきたいワザ22

    増井 健一( 担当: 共著 範囲: TCIポンプを使いこなす)

    克誠堂出版  2014年5月  ( ISBN:9784771904293

     詳細を見る

    総ページ数:vii, 280p   記述言語:日本語  

    CiNii Books

    researchmap

  • 静脈麻酔

    増井 健一( 担当: 共著 範囲: 大量出血を伴う手術や長時間手術の麻酔)

    克誠堂出版  2014年5月  ( ISBN:9784771904262

     詳細を見る

    総ページ数:xv, 367p   記述言語:日本語  

    CiNii Books

    researchmap

  • 周術期モニタリング徹底ガイド : 臨床に役立つ機器のしくみと活用法 : 基本からピットフォールまで

    増井 健一( 担当: 共著 範囲: TCIポンプ(プロポフォール血中濃度))

    羊土社  2013年11月  ( ISBN:9784758111096

     詳細を見る

    総ページ数:329p   記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔・集中治療とテクノロジー2012

    増井 健一( 担当: 共著 範囲: Excel上でRを使う)

    日本麻酔・集中治療テクノロジー学会  2013年10月 

     詳細を見る

  • あらゆる科で役立つ!麻酔科で学びたい技術 : 手にとるようにわかる,麻酔の基本概念と手技・周術期管理のポイント,知っておくべき病態の知識

    増井 健一( 担当: 共著 範囲: TIVAによる麻酔法)

    羊土社  2013年6月  ( ISBN:9784758105507

     詳細を見る

    総ページ数:261p   記述言語:日本語  

    CiNii Books

    researchmap

  • オピオイド : 基礎を知って臨床で使いこなす

    増井 健一( 担当: 共著 範囲: オピオイドのPK/PD)

    克誠堂出版  2012年6月  ( ISBN:9784771903968

     詳細を見る

    総ページ数:vii, 209p   記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔・集中治療とテクノロジー2009

    萩平哲, 増井健一, 高階雅紀, 内田整, 森隆比古( 担当: 共著 範囲: 薬物をボーラス投与した時の薬物動態モデル)

    日本麻酔・集中治療テクノロジー学会  2012年4月 

     詳細を見る

  • 麻酔・集中治療とテクノロジー2011

    増井健一, 萩平哲, 風間富栄( 担当: 共著 範囲: 薬物をボーラス投与した時の薬物動態モデル)

    日本麻酔・集中治療テクノロジー学会  2012年4月 

     詳細を見る

  • 麻酔科薬剤ノート : 周術期の麻酔・救急対応薬の使用のポイント

    増井 健一( 担当: 共著 範囲: 降圧薬/冠血管拡張)

    羊土社  2010年6月  ( ISBN:9784758111010

     詳細を見る

    総ページ数:285p   記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔・集中治療とテクノロジー2006

    増井 健一( 担当: 共著 範囲: Excel でデータ入力から基本統計まで)

    日本麻酔・集中治療テクノロジー学会  2009年9月 

     詳細を見る

  • 麻酔の現況と展望 : 研修医と指導医のための質問317

    増井 健一( 担当: 共著 範囲: オピオイド(麻薬))

    総合医学社  2009年5月  ( ISBN:9784883786008

     詳細を見る

    総ページ数:278p   記述言語:日本語  

    CiNii Books

    researchmap

  • 今日から実践できるTIVA [2]

    増井 健一( 範囲: レミフェンタニルを用いた麻酔導入)

    真興交易医書出版部  2008年4月  ( ISBN:9784880038100

     詳細を見る

    記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔・集中治療とテクノロジー2005

    増井 健一( 担当: 共著 範囲: Excel のグラフ機能を使いこなす)

    日本麻酔・集中治療テクノロジー学会  2006年11月 

     詳細を見る

  • 麻酔・集中治療とテクノロジー2004

    増井 健一( 担当: 共著 範囲: 統計データの正しい解釈のために)

    日本麻酔・集中治療テクノロジー学会  2006年9月 

     詳細を見る

  • 今日から実践できるTIVA

    増井 健一( 担当: 共著 範囲: 総論Ⅱ Goog risk 症例におけるTIVA の実際-調節するにはプロポフォールか?オピオイドか?-)

    真興交易医書出版部  2006年6月  ( ISBN:9784880037677

     詳細を見る

    記述言語:日本語  

    CiNii Books

    researchmap

  • コ・メディカルのための統計学入門 : これさえあれば,論文作成・学会発表なんか怖くない!

    増井 健一( 担当: 共著 範囲: メタ・アナリシス)

    日本放射線技師会出版会  2005年11月  ( ISBN:4861570069

     詳細を見る

    総ページ数:199p   記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔・集中治療とテクノロジー2003

    増井 健一( 担当: 共著 範囲: 活用しようPDF 利用〜作成〜論文投稿)

    日本麻酔・集中治療テクノロジー学会  2004年12月 

     詳細を見る

  • ここからはじめるメタ・アナリシス : Excelを使って簡単に

    増井 健一( 担当: 単著)

    真興交易医書出版部  2003年6月  ( ISBN:4880037001

     詳細を見る

    総ページ数:135p   記述言語:日本語  

    CiNii Books

    ASIN

    researchmap

  • 静脈麻酔/TCIソフトウェアガイドブック : 研修医からエキスパートまで

    増井 健一( 担当: 共著 範囲: BeConSim)

    克誠堂出版  2003年5月  ( ISBN:4771902623

     詳細を見る

    総ページ数:168p   記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔・集中治療とテクノロジー2002

    増井 健一( 担当: 共著 範囲: 再利用可能なBIS センサーの試作)

    2003年2月 

     詳細を見る

  • 手術室,ICUにおけるLANのノウハウ

    増井 健一( 担当: 共著 範囲: パーソナルコンピュータでシリンジポンプを操作する―通信ソフトウェア開発のために―)

    真興交易(株)医書出版部  2003年2月  ( ISBN:4880036900

     詳細を見る

    総ページ数:279p   記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔・集中治療とテクノロジー2001

    増井 健一( 担当: 共著 範囲: ソフトウェアのユーザーインターフェイス ー 使いやすさを考える ー; 年齢によるpharmacodynamics の影響を取り入れたTCI ソフトウェア)

    日本麻酔・集中治療テクノロジー学会  2002年7月 

     詳細を見る

  • ドクター,ナースのためのPalm活用ガイド

    増井 健一( 担当: 共著 範囲: 辞書ソフトKDIC の使用方法; ビューワJ-Doc Reader の使用方法)

    南江堂  2002年5月  ( ISBN:4524235485

     詳細を見る

    総ページ数:ix, 148p   記述言語:日本語  

    CiNii Books

    researchmap

  • 麻酔・集中治療とテクノロジー2000

    増井 健一( 担当: 共著 範囲: Windows95/98 で動くプロポフォール薬物動態シミュレーションソフトの試作)

    日本麻酔・集中治療テクノロジー学会  2001年1月 

     詳細を見る

  • The hypertrophied heart

    Kenichi Masui, Takeshi Oguchi, Satoshi Kashimoto( 担当: 共著 範囲: Effects of melatonin on cardiac function and metabolism in the ischemic working rat heart)

    Kluwer Academic Publishers  2000年9月  ( ISBN:0792377419

     詳細を見る

    総ページ数:xiv, 469 p.   記述言語:英語  

    CiNii Books

    researchmap

▼全件表示

MISC

▼全件表示

受賞

  • Joint 1st place

    2024年9月   Association of Anaesthetists Annual Meeting 2024   Machine learning model for predicting arterial pressure using drug concentrations

    Kenichi Masui. Hroshi Makazu

     詳細を見る

  • JSIVA賞

    2020年11月   第27回日本静脈麻酔学会  

     詳細を見る

  • 第26回日本静脈麻酔学会JSIVA賞

    2019年11月  

     詳細を見る

  • 第6回MSD Award

    2018年   日本臨床麻酔学会  

     詳細を見る

  • ベストプレゼンテーション 優秀賞

    2018年   第15回麻酔科学サマーセミナー  

     詳細を見る

  • JSIVA賞

    2015年   第22回日本静脈麻酔学会  

     詳細を見る

  • JSIVA賞

    2013年   第20回日本静脈麻酔学会  

     詳細を見る

  • JSIVA賞

    2012年   日本静脈麻酔学会  

     詳細を見る

  • JSIVA賞

    2010年   第17回日本静脈麻酔学会  

     詳細を見る

  • Three Best Abstracts

    2010年   13th EuroSIVA Annual Scientific Meeting  

    増井 健一

     詳細を見る

  • JSIVA賞

    2009年   第16回日本静脈麻酔学会  

     詳細を見る

  • 日本麻酔科学会ソフトウェアコンテスト優秀賞

    2007年  

    増井 健一

     詳細を見る

  • 日本麻酔科学会ソフトウェアコンテスト優秀賞

    2001年  

     詳細を見る

    受賞国:日本国

    researchmap

  • The excellent prize of Sotware Contest of the Japanese Society of Anesthesialogists

    2001年  

     詳細を見る

  • The utility prize of Software Contest of Japanese Society of Anesthesiologists

    2000年  

     詳細を見る

  • 日本麻酔科学会ソフトウェアコンテスト実用賞

    2000年  

     詳細を見る

    受賞国:日本国

    researchmap

▼全件表示

共同研究・競争的資金等の研究課題

  • 全身麻酔を施行する小児手術患者におけるレミマゾラムの有効性、安全性および薬物動態を検討するための第III相医師主導治験

    2023年4月 - 2027年3月

    国立研究開発法人日本医療研究開発機構  臨床研究・治験推進研究事業 

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 機械学習・統計解析・薬物動態力学解析を組み合わせた麻酔薬理研究

    研究課題/領域番号:22K09030  2022年4月 - 2025年3月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    増井 健一

      詳細を見る

    配分額:4160000円 ( 直接経費:3200000円 、 間接経費:960000円 )

    researchmap

  • 統合レジストリによる多発性筋炎/皮膚筋炎関連間質性肺疾患の個別化医療基盤の構築

    2021年 - 2024年

    国立研究開発法人日本医療研究開発機構  難治性疾患実用化研究事業 

      詳細を見る

    担当区分:研究分担者  資金種別:競争的資金

    researchmap

  • 呼気プロポフォール連続測定の臨床使用のための基盤研究

    2018年 - 2022年

    文部科学省  科学研究費助成事業 

      詳細を見る

    担当区分:研究代表者 

    researchmap

  • 術中覚醒を減少させるための麻酔関連薬剤の薬物動態力学研究

    2011年 - 2014年

    文部科学省  科学研究費補助金 

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

社会貢献活動

  • 第9回 マダガスカル口唇口蓋裂医療協力

    昭和大学  2019年11月 - 2019年12月

     詳細を見る

    種別:その他

    researchmap